Pharmaceuticals, Biotechnology and Life Sciences
Wa’el Hashad Wa’el Hashad, CEO, Longeveron MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage…
Data selected for oral presentation reinforce previous findings on safety and efficacyMALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) — Neuronetics,…
DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company…
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with…
EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results…
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in…
WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for…
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a…
MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) — Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a…
HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its…